Durable Responses to COVID-19 Vaccines Seen in Cancer Patients on Immunotherapy
Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.
American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium
No Benefit With Adjuvant Mitotane in Low/Intermediate-Risk Adrenocortical Carcinoma
Adjuvant mitotane does not improve outcomes in patients with adrenocortical carcinoma at low or intermediate risk of relapse after surgery.
Molecular Features of Primary and Metastatic Sites Differ in Renal Cell Carcinoma
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.
Prostate Radiation Therapy Does Not Affect BCG Efficacy in NMIBC
Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.
High-Risk NMIBC Effectively Treated With a BCG Alternative
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
Novel Immunotherapy Plus BCG Effective for Unresponsive Bladder Cancer
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
Neoadjuvant Chemotherapy Deemed New Standard Care in Urothelial Carcinoma
The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.
Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma
The median progression-free survival was similar between the treatment arms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GU 2022
Loading... 
Loading...